CERUS CORP
No enriched coverage for $CERS in the last 7 days.
No SEC Form 4 filings for $CERS in the last 30 days.
Cerus Corporation reported strong financial results for the first quarter of 2026, with total revenue increasing by 23% to $59.9 million and product revenue by 24% to $53.7 million. The company significantly narrowed its net loss to $1.6 million and saw increased demand for its INTERCEPT Fibrinogen Complex. Based on this performance, Cerus raised its full-year 2026 product revenue guidance to a range of $227 million to $231 million.
Sumitomo Mitsui Trust Group Inc. reduced its stake in Cerus Corporation by 6.3% during the third quarter, selling 384,660 shares and holding 5,685,177 shares valued at $9.04 million. Despite this, other hedge funds like AQR Capital Management and Millennium Management increased their positions, with institutional investors and hedge funds collectively owning 78.37% of the stock. Analyst ratings are mixed, resulting in a consensus "Hold" rating and a $4.00 price target, while Cerus's stock saw a 5.1% drop to $2.60.
Image source: The Motley Fool.Tuesday, November 4, 2025 at 11:30 a.m. ETChief Executive Officer - Michael CombsContinue reading ...
